Global Breast Biopsy Devices Market Size & Trends Report Segmented by Product (Biopsy Needles, Guidance Systems, Biopsy Tables), Application (Early Screening, Therapy Selection, Treatment Monitoring), End-user Analysis & Regional Forecast to 2030

The global breast biopsy devices market is expected to grow at a CAGR of ~6% during the forecast period. Increase in the incidence of breast cancer, technological advancements in the image-guided techniques, expansion of breast cancer screening programs, and growing preference for minimally invasive techniques are some of the key driving factors supporting market growth. To learn more about the research report, download a sample report.

Overview

Breast biopsy devices are specialized tools designed to help clinicians accurately identify and diagnose abnormalities in breast tissue, particularly when early signs of cancer are suspected. There are several types of breast biopsy techniques, each requiring specific devices.

• Core Needle Biopsy (CNB): Uses a hollow needle to remove tissue samples, typically guided by imaging technologies such as ultrasound, mammography (stereotactic biopsy), or MRI
• Vacuum-Assisted Biopsy (VAB): Utilizes suction to extract multiple tissue samples through a single needle insertion, offering higher accuracy with fewer complications
• Fine Needle Aspiration (FNA): Involves a thin needle to collect fluid or cells, commonly used for cysts or small nodules
• Surgical Biopsy: A more invasive procedure where part or all of a suspicious mass is surgically removed for examination

These imaging techniques support precise targeting of suspicious areas, making the procedure safer and more comfortable for patients while reducing the need for surgical intervention.

To learn more about this report, download the PDF brochure

AI and imaging innovation are transforming accuracy in breast biopsy devices

Rapid advancements in image-guided techniques have transformed breast biopsy procedures by making them less invasive and more accurate. The integration of imaging modalities such as ultrasound, magnetic resonance imaging (MRI), and stereotactic mammography allows clinicians to precisely localize suspicious lesions within breast tissue, thereby facilitating accurate needle placement during biopsy. This precision facilitates the early detection of malignancies and significantly reduces the likelihood of false negatives.

Recent developments in imaging systems and the compatibility of biopsy devices with various imaging platforms have also contributed to a more patient-friendly and efficient diagnostic experience. The use of smaller, more refined instruments enables efficient tissue sampling with minimal discomfort and eliminates the need for surgical intervention in many cases. Moreover, the incorporation of artificial intelligence (AI) into imaging workflows is transforming breast cancer detection and biopsy accuracy. According to the Breast Cancer Research Foundation (BCRF), AI algorithms can make diagnostic labs' workflow more efficient and minimize human bias, while AI-powered software can automate the interpretation of mammograms, ultrasounds, and MRI scans, allowing patients to receive results faster and with greater consistency. Furthermore, the improved visualization provided by advanced imaging reduces the incidence of repeat procedures, enhancing diagnostic efficiency. Collectively, these innovations have reinforced the clinical utility of image-guided biopsy techniques and promoted their integration into routine breast cancer diagnostic pathways.

To learn more about this report, download the PDF brochure

Growing adoption of ultrasound-guided biopsy accelerates market expansion

The widespread use of ultrasound-guided biopsy is gaining traction in the breast biopsy devices market, as this method is preferred for its lower invasiveness, accurate targeting of suspicious areas, and reduced need for repeat procedures. This method enables real-time imaging, thereby allowing clinicians to adjust the needle placement dynamically with improved diagnostic accuracy. Compared to other biopsy techniques, the ultrasound-guided procedure involves lower radiation exposure, which has made this diagnostic technology safer for younger patients and ideal for those undergoing routine screenings. Moreover, innovations in device design, such as vacuum-assisted and portable systems, have further improved the effectiveness and ease of use of these procedures, particularly in ambulatory and low-resource settings. With the expansion in breast cancer screening programs globally, ultrasound-guided biopsy is emerging as a vital component of modern breast diagnostics.

Competitive Landscape Analysis

The global breast biopsy devices market is marked by the presence of established and emerging market players such as Hologic Inc.; Danaher Corporation; Becton, Dickinson and Company; Argon Medical Devices, Inc.; Merit Medical Systems,Inc.; Fujifilm Corporation; Hoffman La-Roche Ltd.; QIAGEN; Cook Medical Inc.; and Devicor Medical Products Inc., among others.

Report Scope

Growth Rate

Report Metric	Details
Base Year Considered	2024
Historical Data	2023 - 2024
Forecast Period	2025 - 2030
~6%
Market Drivers	Increase in incidence of breast cancer Growing preference for minimally invasive techniques Technological advancement in image-guided techniques Expansion of breast cancer screening programs Growing healthcare investments and improved diagnostic infrastructure
Attractive Opportunities	Growing demand for portable and handheld biopsy devices Increasing R&D for AI-driven biopsy navigation and automation tools Strategic collaborations and mergers enhancing product portfolios
Segment Scope	Product, Application, and End-user
Regional Scope	North America (US & Canada) Europe (UK, Germany, France, Italy, Spain, Rest of Europe) Asia Pacific (China, India, Japan, Rest of Asia Pacific) Latin America Middle East & Africa
Key Companies Mapped	Hologic Inc.; Danaher Corporation; Becton,Dickinson and Company; Argon Medical Devices,Inc.; Merit Medical Systems,Inc.; Fujifilm Corporation; Hoffman La-Roche Ltd.; QIAGEN; Cook Medical Inc.; Devicor Medical Products Inc.; among others
Report Highlights	Market Size & Forecast, Growth Drivers & Restraints, Trends, Competitive Analysis

������

Global Breast Biopsy Devices Market Segmentation

This report by Medi-Tech Insights provides the size of the global breast biopsy devices market at the������regional- and country-level from 2023 to 2030. The report further segments the market based on product, application, and end-user.

Market Size & Forecast (2023-2030), By Product, USD Million

• Biopsy Needles
• Guidance Systems
• Biopsy Tables
• Liquid Biopsy Instruments
• Localization Wires
• Others

Market Size & Forecast (2023-2030), By Application, USD Million

• Early Screening
• Therapy Selection
• Treatment Monitoring
• Reoccurrence Monitoring

Market Size & Forecast (2023-2030), By End-user, USD Million

• Hospitals
alty Clinics
• Ambulatory Surgical Centers
• Others

Market Size & Forecast (2023-2030), By Region, USD Million

• North America
  • US
  • Canada
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Rest of Asia Pacific
• Latin America
• Middle East & Africa

Key Strategic Questions Addressed

• What is the market size & forecast of the breast biopsy devices market?
• What are historical, present, and forecasted market shares and growth rates of various segments and sub-segments of the breast biopsy devices market?
• What are the key trends defining the market?
• What are the major factors impacting the market?
• What are the opportunities prevailing in the market?
• Which region has the highest share in the global market? Which region is expected to witness the highest growth rate in the next 5 years?
• Who are the major players operating in the market?
• What are the key strategies adopted by players?